SA’s medicines regulator says it does not anticipate suspending use of the Johnson & Johnson (J&J) coronavirus vaccine after US authorities warned earlier this week of a possible association with a rare neurological condition called Guillain-Barre syndrome.

The J&J shot is one of two vaccines being administered in the national coronavirus inoculation drive and is central to the government’s plans to reach 70% of the adult population by March 2022...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.